Public Health.

Background: Impaired functional status is a central diagnostic feature of Alzheimer's disease and related dementias (ADRD). Informant reporting is often relied upon, given concerns surrounding the ability of persons with ADRD to validly self-report symptoms. We sought to investigate how cognitive impairment severity impacts psychometric properties of the Patient-Reported Outcomes Measurement Information System Physical Function (PROMIS-PF) scale.

Dementia Care Practice.

Introduction: Patient-reported outcomes are increasingly being utilized in clinical settings to identify psychological symptoms and track fluctuations over time. Some clinicians and researchers have expressed concerns about the validity of symptom questionnaires cognitively impaired populations. We sought to determine if differential item functioning (DIF) is present based on cognitive impairment using the patient reported outcomes measurement information system (PROMIS) inventories of anxiety and depression.

The growing range of complications of diabetes mellitus.

With the rising prevalence of type 2 diabetes mellitus (T2DM) and obesity, several previously under-recognised complications associated with T2DM are becoming more evident. The most common of these emerging complications are metabolic dysfunction-associated steatotic liver disease (MASLD), cancer, dementia, sarcopenia, and frailty, as well as other conditions involving the lung, heart, and intestinal tract. Likely causative factors are chronic inflammation and insulin resistance, whereas blood glucose levels appear to play a lesser role.

Cardiovascular effects of tirzepatide.

Tirzepatide is a first-in-class dual agonist at receptors for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) for the treatment of T2D and obesity with unprecedented efficacy for glycaemic control and reductions in body weight as well as improvements in blood pressure and lipid profile compared with placebo and GLP-1 receptor agonists. To date, clinical trials of tirzepatide have fulfilled the requirement by regulatory authorities of demonstrated cardiovascular safety in high-risk patients. Whether cardiovascular benefits will be found with dual GLP-1/GIP receptor agonists remains uncertain, and the contribution of GIP receptor activation to cardiovascular risk has not been established.

Cardio-metabolic and cytoskeletal proteomic signatures differentiate stress hypersensitivity in dystrophin-deficient mdx mice.

Extreme heterogeneity exists in the hypersensitive stress response exhibited by the dystrophin-deficient mdx mouse model of Duchenne muscular dystrophy. Because stress hypersensitivity can impact dystrophic phenotypes, this research aimed to understand the peripheral pathways driving this inter-individual variability. Male and female mdx mice were phenotypically stratified into "stress-resistant" or "stress-sensitive" groups based on their response to two laboratory stressors.